Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Journal Article (Journal Article;Review)

Improved understanding of soft-tissue sarcoma (STS) biology has led to better distinction and subtyping of these diseases with the hope of exploiting the molecular characteristics of each subtype to develop appropriately targeted treatment regimens. In the care of patients with extremity STS, adjunctive radiation therapy (RT) is used to facilitate limb and function, preserving surgeries while maintaining five-year local control above 85%. In contrast, for STS originating from nonextremity anatomical sites, the rate of local recurrence is much higher (five-year local control is approximately 50%) and a major cause of death and morbidity in these patients. Incorporating novel technological advancements to administer accurate RT in combination with novel radiosensitizing agents could potentially improve local control and overall survival. RT efficacy in STS can be increased by modulating biological pathways such as angiogenesis, cell cycle regulation, cell survival signaling, and cancer-host immune interactions. Previous experiences, advancements, ongoing research, and current clinical trials combining RT with agents modulating one or more of the above pathways are reviewed. The standard clinical management of patients with STS with pretreatment biopsy, neoadjuvant treatment, and primary surgery provides an opportune disease model for interrogating translational hypotheses. The purpose of this review is to outline a strategic vision for clinical translation of preclinical findings and to identify appropriate targeted agents to combine with radiotherapy in the treatment of STS from different sites and/or different histology subtypes.

Full Text

Duke Authors

Cited Authors

  • Wong, P; Houghton, P; Kirsch, DG; Finkelstein, SE; Monjazeb, AM; Xu-Welliver, M; Dicker, AP; Ahmed, M; Vikram, B; Teicher, BA; Coleman, CN; Machtay, M; Curran, WJ; Wang, D

Published Date

  • November 2014

Published In

Volume / Issue

  • 106 / 11

PubMed ID

  • 25326640

Pubmed Central ID

  • PMC4207861

Electronic International Standard Serial Number (EISSN)

  • 1460-2105

Digital Object Identifier (DOI)

  • 10.1093/jnci/dju329


  • eng

Conference Location

  • United States